Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Hutchison MediPharma Starts Phase III Trial of Cancer Drug

publication date: Dec 17, 2014
Last week, Hutchison MediPharma, a division of Chi-Med, dosed the first patient in a China Phase III clinical trial of fruquintinib (HMPL-013), a treatment for solid tumor cancers. The trial will enroll more than 400 patients with advanced colorectal cancer who have already failed two previous antineoplastic therapies. In 2013, Hutchison MediPharma out-licensed China rights for fruquintinib to Lilly in a deal worth up to $86.5 million in upfront and milestone payments. More details....

Stock Symbols: (AIM: HCM) (NYSE: LLY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital